Palisade Bio wins Health Canada clearance for ASCENTRA-UC Phase 2 trial of PALI-2108
PALI•Primary data expected in 2H 2027
Primary efficacy data from the 12-week induction phase is expected in 2H 2027.
Health Canada clears ASCENTRA-UC trial application
Health Canada cleared Palisade Bio’s clinical trial application for its global Phase 2b ASCENTRA-UC study of oral PALI-2108.
The decision enables Canadian site activation, supporting enrollment of about 204 patients with moderate-to-severe ulcerative colitis.
